In “Editing Humanity,” Kevin Davies offers an account of Crispr at a moment when its leading American researcher has just won the Nobel Prize in Chemistry.
Impatient for a coronavirus vaccine, dozens of scientists around the world are giving themselves — and sometimes, friends and family — their own unproven versions.
Bayer faced tens of thousands of claims linking the weedkiller to cases of non-Hodgkin’s lymphoma. Some of the money is set aside for future cases.
Modern medicine still depends on this animal’s blood to test for bacteria in vaccines. And an alternative test requires further study.
The desperate hunt for treatments and vaccines has changed how researchers, regulators, drug companies like Moderna, investors and journalists do their jobs.
Moncef Slaoui, a former pharmaceutical executive, is now overseeing the U.S. initiative to development coronavirus treatments and vaccines. His financial interests and corporate roles have come under scrutiny.
Moncef Slaoui, a former pharmaceutical executive the White House chose to lead a crash development program, acknowledged that the 12-18 month timeline cited by Dr. Anthony Fauci was already “very aggressive.”
The company announced that the Food and Drug Administration had cleared its application to proceed to a clinical trial involving about 600 people.
A pioneer of the gene-editing technology has devised a diagnostic test for the infection that could be as simple as a pregnancy test.
By some measures, it is winning the race, with four companies already testing their vaccine candidates on humans.
A team of scientists worked around the clock to evaluate 14 antibody tests. A few worked as advertised. Most did not.
A decade of health disinformation promoted by President Vladimir Putin of Russia has sown wide confusion, hurt major institutions and encouraged the spread of deadly illnesses.